Speedy review for AZ’ Lynparza in breast cancer

19th October 2017 Uncategorised 0

AstraZeneca’s and MSD’s Lynparza is being given a priority review by US regulators as a potential treatment for breast cancer, marking the first time a PARP inhibitor has been filed for an indication outside of ovarian cancer.

More: Speedy review for AZ’ Lynparza in breast cancer
Source: News